论文部分内容阅读
目的探讨CD147在卵巢浆液性和黏液性腺癌中的表达。方法采用免疫组织组化学方法检测石蜡包埋的40例卵巢浆液性腺癌、40例黏液性腺癌和10例正常的卵巢组织的标本中CD147的表达,应用实时荧光定量RT-PCR的方法检测CD147mRAN的相对含量。结果 CD147在正常卵巢组织中不表达,浆液性腺癌中的阳性表率为75%,与正常卵巢组织相比差异有统计学意义(χ2=15.76,P﹤0.05),在黏液腺癌中的阳性表达率为85%,与正常卵巢组织相比差异有统计学意义(χ2=22.79,P﹤0.05),CD147在浆液性腺癌中和黏液腺癌中的表达差异无统计学意义(χ2=1.25,P﹥0.05),CD147的表达程度与卵巢癌的临床分期及病理分级有关。CD147mRNA的相对含量在卵巢浆液性和黏液性腺癌中分别为0.45和0.58。结论 CD147可能是卵巢癌诊断的标志物和治疗的新靶点。
Objective To investigate the expression of CD147 in ovarian serous and mucinous adenocarcinoma. Methods Immunohistochemistry was used to detect the expression of CD147 in 40 specimens of ovarian serous adenocarcinoma, 40 specimens of mucinous adenocarcinoma and 10 specimens of normal ovarian tissue. Real-time quantitative RT-PCR was used to detect the expression of CD147mRAN Relative content. Results CD147 was not expressed in normal ovarian tissue. The positive rate of CD147 in serous adenocarcinoma was 75%, which was significantly different from that of normal ovarian tissue (χ2 = 15.76, P <0.05). The positive expression of CD147 in mucinous adenocarcinoma (Χ2 = 22.79, P <0.05). There was no significant difference in the expression of CD147 between serous adenocarcinoma and mucinous adenocarcinoma (χ2 = 1.25, P > 0.05). The expression of CD147 correlated with the clinical stage and pathological grade of ovarian cancer. The relative amounts of CD147 mRNA in ovarian serous and mucinous adenocarcinomas were 0.45 and 0.58, respectively. Conclusion CD147 may be a new diagnostic and therapeutic target for ovarian cancer.